10/22/2026
UK Markey Cancer Center researchers are uncovering how melanoma protects itself from both treatment and the immune system.
A new study identified the proteins ABL1 and ABL2 as key drivers that help melanoma cells resist targeted therapy while also creating an immune environment that helps the cancer survive. In preclinical models, researchers found that blocking these proteins with nilotinib disrupted cancer growth and survival signals and reduced the cancer’s ability to attract immune-suppressing cells, allowing T-cells to return.
The findings could open new possibilities for overcoming melanoma treatment resistance.
Click the link in our info section to learn more.